UPDATE 3-Cancer trials show 1 year on Roche's Herceptin is best Reuters via Yahoo! Maktoob News Mon, 01 Oct 2012 05:10 AM PDT * Roche trial favours status quo, French trial inconclusive * Experts say key message is one year of Herceptin is best * Results limit downside risk for Roche's Herceptin revenues LONDON, Oct 1 (Reuters) - The results of two studies intoRoche's breast cancer drug Herceptin published onMonday showed that the current standard treatment of taking thedrug for a year provides the best outcome for ... | Breast cancer patients live longer on Roche's TDM-1 Reuters via Yahoo! Maktoob News Mon, 01 Oct 2012 05:09 AM PDT LONDON, Oct 1 (Reuters) - Women with an aggressive type ofadvanced breast cancer who were treated with an experimental"armed antibody" drug from Roche lived more than fivemonths longer than those receiving the standard drug cocktail,researchers said on Monday. Data from a Phase III trial of the drug, called trastuzumabemtansine or TDM-1, in HER2-positive breast cancer, showedpatients treated ... | | |
|
No comments:
Post a Comment